Nanoformulations-based metronomic chemotherapy: mechanism, challenges, recent advances, and future perspectives
Cancer-related death is a significant health and economic burden worldwide, and some
conventional chemotherapy is associated with limited effectiveness in completely curing …
conventional chemotherapy is associated with limited effectiveness in completely curing …
B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors
Y Yang, J Huang, B Hu, J Zhou, X Wang, Z Feng… - World Journal of …, 2022 - Springer
Background Not all lung adenocarcinoma (LUAD) patients with activating epidermal growth
factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended …
factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended …
Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma
Q Yu, L Zhao, X Yan, Y Li, X Chen, X Hu, Q Bu… - World Journal of Surgical …, 2022 - Springer
Background Transforming growth factor (TGF)-β signaling functions importantly in regulating
tumor microenvironment (TME). This study developed a prognostic gene signature based on …
tumor microenvironment (TME). This study developed a prognostic gene signature based on …
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA
H Aggarwal, KO Bayo, Y Han, CE Muehlenbein… - …, 2023 - Future Medicine
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-
squamous non-small-cell lung cancer (NSQ-NSCLC) patients that received pembrolizumab …
squamous non-small-cell lung cancer (NSQ-NSCLC) patients that received pembrolizumab …
[PDF][PDF] Comparison of survival outcomes between clinical trial participants and non-participants of patients with advanced non-small cell lung cancer: A retrospective …
Q Jiang, X Yue, H Lei, W Mao, Y Li, X Chen - Heliyon, 2023 - cell.com
Background Clinical trials for advanced non-small cell lung cancer (NSCLC) have been
conducted extensively. However, the effect of participation in clinical trials on survival …
conducted extensively. However, the effect of participation in clinical trials on survival …
Systematic evaluation of clinical efficacy of CYP1B1 gene polymorphism in EGFR mutant non-small cell lung cancer observed by medical image
S Zhang, D Li, X Han - Open Life Sciences, 2023 - degruyter.com
Lung cancer is the cancer with the highest mortality rate and the highest incidence in the
world at this stage. Among them, non-small lung cancer is the most common type of lung …
world at this stage. Among them, non-small lung cancer is the most common type of lung …
Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors
Z Davoodi-Moghaddam, F Jafari-Raddani, S Kordasti… - 2022 - researchsquare.com
Background Although advances in immune checkpoint inhibitor (ICI) research have
provided a new treatment approach for lung adenocarcinoma (LUAD) patients, their survival …
provided a new treatment approach for lung adenocarcinoma (LUAD) patients, their survival …
[PDF][PDF] A case report of refractory pulmonary adenocarcinoma
H Li, C Xu, X Lu - Adv Radiother Nucl Med, 2023 - api-journal.accscience.com
As one of the most common types of carcinomas, lung cancer has high incidence and
mortality rates. Among the pathological types of lung cancer, pulmonary adenocarcinoma is …
mortality rates. Among the pathological types of lung cancer, pulmonary adenocarcinoma is …